Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New anxiolytic drugs: methodological issues].

D Ginestet1, E Corruble

  • 1Hôpital Paul Brousse, 14, avenue Paul-Vaillant Couturier, 94804 Villejuif.

L'Encephale
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between driving and depression in older adults: findings from an ancillary study of a prospective cohort.

BMC geriatrics·2025
Same author

Non-overweight depressed patients who respond to antidepressant treatment have a higher risk of later metabolic syndrome: findings from the METADAP cohort.

Psychological medicine·2023
Same author

[Advance directives in perinatal psychiatry: A parenting aid for women with bipolar disorder?]

L'Encephale·2022
Same author

Prolonged impact of the COVID-19 pandemic on self-harm hospitalizations in France: A nationwide retrospective observational study.

European psychiatry : the journal of the Association of European Psychiatrists·2022
Same author

Reviving through human hippocampal newborn neurons.

L'Encephale·2021
Same author

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2021

New anxiolytic drugs aim for better safety and efficacy than benzodiazepines. Methodological challenges in clinical trials, including diagnostic criteria and assessment methods, require careful consideration for accurate drug development.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Trials

Context:

  • Anxiety disorders are heterogeneous and often comorbid with depression.
  • Current anxiolytic drug development aims for improved safety profiles compared to benzodiazepines.
  • Methodological challenges impact the reliable assessment of new anxiolytic efficacy and safety.

Purpose:

  • To review and highlight the numerous methodological issues in the development of new anxiolytic drugs.
  • To discuss challenges in diagnostic classification, study design, dosage selection, and outcome assessment.
  • To examine safety assessment methods, including abuse liability, cognitive impairment, and sedative effects.

Summary:

  • Clinical trials for new anxiolytics face challenges in diagnostic definitions, heterogeneity of anxiety disorders, and comorbidity with depression.

Related Experiment Videos

  • Methodological hurdles include determining optimal dosages, appropriate study durations (4-12 weeks short-term, 4-6 months long-term), and selecting validated efficacy and safety assessment tools.
  • Safety evaluations focus on abuse liability, withdrawal syndromes, subjective effects, cognitive impairment, and sedative effects, utilizing various testing batteries and questionnaires.

    • Impact:

    • Addressing these methodological issues is crucial for advancing therapeutic strategies in anxiety disorders.
    • Improved trial designs and assessment tools will lead to more reliable efficacy and safety data for new anxiolytics.
    • Overcoming these challenges ensures the continued development of safer and more effective anxiety treatments.